CULLINAN THERAPEUTICS, INC. Acquisitions, Net of Cash Acquired
CULLINAN THERAPEUTICS, INC. (CGEM) reported Acquisitions, Net of Cash Acquired of -$1.45 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-17.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2022-03-17
- CULLINAN THERAPEUTICS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2020-12-31 was $0.00.
- CULLINAN THERAPEUTICS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2020-09-30 was $0.00.
- CULLINAN THERAPEUTICS, INC. payments to acquire businesses, net of cash acquired for fiscal 2020 was -$1.45M.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | -$1.45M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$1.45M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | -$1.45M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |